Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis.
NCT ID: NCT02847156
Last Updated: 2016-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2015-01-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to assess the frequency of lower and upper RVI during a 1 year follow-up in CF infants and to evaluate the impact of RVI at a clinical, microbiological and therapeutic level.
Our hypothesis is that frequent and/or clinically severe RVIs have the worst impact in the short term and without any particular link with a specific virus as previously described.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
NCT04026360
Respiratory Function at Preschool Age of Children Detected of Cystic Fibrosis in Neonatal Period
NCT02358798
Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis
NCT06188988
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
NCT01973192
The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults
NCT01238081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cystic fibrosis infants
1 year follow-up in CF infants
Physical assessment
1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Physical assessment
1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
24 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stéphanie VRIELYNCK, MD
Role: PRINCIPAL_INVESTIGATOR
Cystic Fibrosis Pediatric Reference Centrer, Hospices Civils de Lyon, 69677 Bron Cedex, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cystic Fibrosis Pediatric Reference Centrer, Hospices Civils de Lyon
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL14_0276
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.